Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for cancer therapy–induced thrombocytopenia in solid tumors (real‑world, single‑center)
ChiCTR2600124107Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Thrombocytopenia and Non-hematologic malignancy, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Proportion of response cycles. Planned start May 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
ThrombocytopeniaNon-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2600124107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124107.